Clinical Trials in Tustin, California

22 recruiting

Showing 120 of 22 trials

Recruiting
Phase 3

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic
Janssen Research & Development, LLC600 enrolled69 locationsNCT07438496
Recruiting

MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study

Lumbar Spinal Stenosis
Stryker Instruments8,000 enrolled2262 locationsNCT03072927
Recruiting
Phase 3

A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease

Immunoglobulin G4-Related Disease
Sanofi124 enrolled68 locationsNCT07190196
Recruiting
Phase 3

A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout

Uncontrolled Gout
Amgen270 enrolled37 locationsNCT07388498
Recruiting
Phase 3

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

Heart Failure
Boehringer Ingelheim6,000 enrolled653 locationsNCT06424288
Recruiting
Phase 3

Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)

Complex Regional Pain Syndrome Type I
Ambros Therapeutics, Inc.270 enrolled6 locationsNCT07210515
Recruiting
Phase 2

A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)

Active Rheumatoid Arthritis
Elevara Medicines Limited180 enrolled29 locationsNCT07409103
Recruiting
Phase 3

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

ObesityOverweight
Eli Lilly and Company1,980 enrolled173 locationsNCT07321886
Recruiting
Phase 3

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

ObesityOverweight
Eli Lilly and Company900 enrolled178 locationsNCT07392190
Recruiting
Phase 2

A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin

Diabetes Mellitus, Type 2
Eli Lilly and Company100 enrolled26 locationsNCT07215312
Recruiting
Phase 3

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

HypertensionHigh Risk Cardiovascular DiseaseHigh Cardiovascular Risk
Alnylam Pharmaceuticals11,000 enrolled597 locationsNCT07181109
Recruiting
Phase 3

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

Urinary Incontinence, Stress
Eli Lilly and Company1,000 enrolled136 locationsNCT07202884
Recruiting
Phase 3

A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

Diabetes Mellitus, Type 1
Novo Nordisk A/S877 enrolled193 locationsNCT07076199
Recruiting
Phase 2

A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)

Urinary Tract Infections
Locus Biosciences318 enrolled17 locationsNCT05488340
Recruiting
Phase 2

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca1,160 enrolled363 locationsNCT07082738
Recruiting
Phase 3

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
AbbVie1,000 enrolled369 locationsNCT05843643
Recruiting
Phase 3

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

Weight Loss
Viking Therapeutics, Inc.1,100 enrolled134 locationsNCT07104383
Recruiting
Phase 2

Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)

Interstitial CystitisBladder Pain Syndrome
Vaneltix Pharma, Inc.50 enrolled5 locationsNCT06394830
Recruiting
Phase 2

Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS

Interstitial CystitisBladder Pain Syndrome
Vaneltix Pharma, Inc.120 enrolled14 locationsNCT05737121
Recruiting
Phase 2

A Study of RSLV-132 in Females With Sjögren's Disease

Primary Sjögren Syndrome
Resolve Therapeutics106 enrolled24 locationsNCT06440525